Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma
Clinical trial NCT07328802 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07328802
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-01
- Primary completion
- 2028-09-30
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.